CMS Rejects HHS Call for Off-Label Avastin Endorsement

Medicare administrators are shooting down recommendations in a government study released Monday that adds fresh ammunition to claims off-label use of cancer drug Avastin for eye disease could save taxpayers billions of dollars.
Law360